Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Cash & Equivalents data on file, last reported at $755.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 30.17% year-over-year to $755.9 million; the trailing twelve-month figure through Mar 2026 stood at $755.9 million (up 30.17% YoY), and the FY2025 full-year result was $709.2 million, up 37.02% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $755.9 million, up from $709.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $755.9 million in Q1 2026 and bottomed at $121.0 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $310.4 million (2024), against an average of $386.1 million.
• The widest annual swing landed in 2023, when Cash & Equivalents tumbled 53.87%; it then jumped 276.03% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $298.4 million in 2022, then sank by 53.87% to $137.6 million in 2023, then surged by 276.03% to $517.6 million in 2024, then soared by 37.02% to $709.2 million in 2025, then rose by 6.58% to $755.9 million in 2026.
• The last three Cash & Equivalents figures came in at $755.9 million (Q1 2026), $709.2 million (Q4 2025), and $689.9 million (Q3 2025), per Business Quant data.

Peer Comparison